Virtual CE Symposium

Transforming Progress Into Action in Relapsed/Refractory Multiple Myeloma:
Improving Patient Outcomes Through Innovative Bispecific Antibodies

Sunday, May 26, 2024
Virtual CE Symposium – 11:30 AM CEST – 12:30 PM CEST

Activity Overview

The emergence of bispecific antibodies in multiple myeloma have revolutionized treatment, providing a much-needed therapeutic option for patients who are relapsed or refractory to multiple lines of therapy. In this CME-certified educational activity, 3 multiple myeloma experts will review the key clinical trial and real-world data for bispecific antibodies (BsAbs) in the treatment of relapsed/refractory multiple myeloma (RRMM). Using clinical cases as a guide, the experts will discuss factors that influence treatment selection in heavily refractory patients, strategies for choosing between BsAbs and chimeric antigen receptor T-cell therapy, and how to sequence BsAbs in the overall treatment plan. Key considerations when integrating BsAbs into clinical practice, such as infrastructure requirements, dosing and administration, side effects, and patient education, also will be discussed.

TARGET AUDIENCE – This initiative is intended for European hematologist/oncologists, oncologists, advanced practice clinicians, and other healthcare providers involved in the care of patients with RRMM.


Mohamad Mohty, MD, PhD (Course Director)
Sorbonne University
Paris, France

Lisa Leypoldt, MD
University Medical Center Hamburg-Eppendorf, Germany
Dana Farber Cancer Institute/Harvard Medical School
Boston, MA, USA

Salomon Manier, MD
Professor of Medicine
University of Lille
Lille, France

Introduction: Unmet Needs in RRMM
BsAb Therapy in RRMM: Latest Evidence and Clinical Experience
Clinical Case Challenge: Integrating BsAbs Into Management
Clinical Case Challenge: Optimizing the Delivery of BsAbs
Q&A and Closing Remarks

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Evaluate the biologic rationales, mechanisms of action, and most recent efficacy and safety evidence supporting the use of BsAb therapies for RRMM.
  • Formulate individualized treatment approaches that effectively incorporate BsAb therapies into treatment algorithms for patients with RRMM.
  • Employ collaborative strategies to monitor and manage adverse events associated with BsAb therapies in patients with RRMM.
  • Develop strategies to optimize the delivery of BsAb therapies in patients with RRMM, addressing key considerations such as treatment administration, dosing, safety, care coordination, and patient education.

This activity is jointly provided by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC.

This activity is supported by an educational grant from Pfizer.

Criteria for Success
Certificates of completion will be awarded based on the participant’s attendance and submission of the activity evaluation/claim credit form. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at [email protected].

Credit provided by AKH Inc., Advancing Knowledge in Healthcare

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Catalyst Medical Education, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Transforming Progress Into Action In Relapsed/Refractory Multiple Myeloma: Improving Patient Outcomes Through Innovative Bispecific Antibodies has been reviewed and approved for CME-CPD accreditation by the European Board for Accreditation in Hematology (EBAH). The EBAH has approved this educational activity for a maximum number of [insert the allocated number] CME-CPD credits. Each participant should only collect credits for time that she/he actually spent in the educational activity.

For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.

An application for credit has been submitted to the European Board for Accreditation in Hematology. Notification of credit will be disclosed onsite and at the website as well.

Type of Activity: Application-based

Fee Information: There is no fee for this educational activity.